Exo-S-mecamylamine formulation and use in treatment
A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
1. A method of treating a human suffering from depression, the method comprising administering to the human in need thereof, a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, the amount being sufficient to decrease the signs and symptoms of depression; wherein the therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, is characterized by a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
2. The method of claim 1 , wherein the therapeutically effective amount is from about 0.001 mg/kg to about 6 mg/kg per day.
3. The method of claim 1 , wherein the therapeutically effective amount is from about 0.002 mg/kg to about 3 mg/kg per day.
4. The method of claim 1 , wherein the therapeutically effective amount is from about 0.005 mg/kg to about 2 mg/kg per day.
5. The method of claim 1 , wherein the therapeutically effective amount is from about 0.01 to about 1.5 mg/kg per day.
6. The method of claim 1 , wherein the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof is administered in a controlled release dosage form.
7. A method of treating a human suffering from an anxiety disorder, the method comprising administering to the human in need thereof, a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, the amount being sufficient to decrease the signs and symptoms of the anxiety disorder; wherein the therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, is characterized by a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
8. The method of claim 7 , wherein the therapeutically effective amount is from about 0.001 mg/kg to about 6 mg/kg per day.
9. The method of claim 7 , wherein the therapeutically effective amount is from about 0.002 mg/kg to about 3 mg/kg per day.
10. The method of claim 7 , wherein the therapeutically effective amount is from about 0.005 mg/kg to about 2 mg/kg per day.
11. The method of claim 7 , wherein the therapeutically effective amount is from about 0.01 to about 1.5 mg/kg per day.
12. The method of claim 7 , wherein the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof is administered in a controlled release dosage form.
13. A method of treating a human suffering from bipolar disorder, the method comprising administering to the human in need thereof, a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, the amount being sufficient to decrease the signs and symptoms of the bipolar disorder; wherein the therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine is characterized by a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
14. The method of claim 13 , wherein the therapeutically effective amount is from about 0.001 mg/kg to about 6 mg/kg per day.
15. The method of claim 13 , wherein the therapeutically effective amount is from about 0.002 mg/kg to about 3 mg/kg per day.
16. The method of claim 13 , wherein the therapeutically effective amount is from about 0.005 mg/kg to about 2 mg/kg per day.
17. The method of claim 13 , wherein the therapeutically effective amount is from about 0.01 to about 1.5 mg/kg per day.
18. The method of claim 13 , wherein the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof is administered in a controlled release dosage form.
19. A method of treating a human suffering from a neuropsychiatric disorder, the method comprising administering to the human in need thereof, a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, wherein the therapeutically effective amount is from about 0.001 mg/kg to about 6 mg/kg per day; wherein the therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt, thereof substantially free of exo-R-mecamylamine, is characterized by a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
20. The method of claim 19 , wherein the therapeutically effective amount is from about 0.002 mg/kg to about 3 mg/kg per day.
21. The method of claim 19 , wherein the therapeutically effective amount is from about 0.005 mg/kg to about 2 mg/kg per day.
22. The method of claim 19 , wherein the therapeutically effective amount is from about 0.01 to about 1.5 mg/kg per day.
23. The method of claim 19 , wherein the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof is administered in a controlled release dosage form.
24. A pharmaceutical composition comprising
a) a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine; and
b) a pharmaceutically acceptable carrier;
wherein the pharmaceutical composition is characterized by a higher overall therapeutic index than a substantially similar pharmaceutical composition comprising exo-R-mecamylamine substantially free of exo-S-mecamylamine.
25. The composition of claim 24 where the composition is a dosage form comprising from about 0.5 mg to about 2.5 mg exo-S-mecamylamine or a pharmaceutically acceptable salt thereof.
26. The composition of claim 24 which is adapted for administration intravenously, transdermally, orally, intramuscularly, intrathecally or by bolus injection.
27. The composition of claim 24 wherein the composition is a dosage form is adapted for use in a transdermal formulation or patch, solid or liquid preparation, sustained release form, tablet, capsule or gel cap.
28. The pharmaceutical composition of claim 24 wherein the substantially pure exo-S-mecamylamine is greater than 98% by weight and exo-R-mecamylamine is less than 2% by weight.
29. The pharmaceutical composition of claim 24 wherein the substantially pure exo-S-mecamylamine is greater than greater than 99% by weight and exo-R-mecamylamine is less than 1% by weight.
30. The pharmaceutical composition of claim 24 wherein the substantially pure exo-S-mecamylamine is greater than 99.5% by weight and exo-R-mecamylamine is less than 0.5% by weight.
31. The pharmaceutical composition of claim 24 wherein the substantially pure exo-S-mecamylamine is greater than 99.7% by weight and exo-R-mecamylamine is less than 0.3% by weight.
32. The pharmaceutical composition of claim 24 which is adapted for administration by bronchial inhalation.